Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

(Reuters) -Bristol Myers Squibb beat Wall Street estimates for third-quarter revenue on Thursday, as strong growth of its ...

As momentum for Biogen’s newer drugs for neurological disorders builds at a slow and steady pace, it appears that the company ...

UCSF scientists reveal how the KLF15 protein converts white fat into brown fat that burns energy, offering new hope for ...

For patients newly diagnosed with Crohn’s disease, initiating anti-TNF therapy early led to better outcomes and lower overall ...

Rosnilimab acts as an agonist to stimulate PD-1, killing those cells with high PD-1 expression and pushing others into an ...

With vaccine sales on the decline, these are tough times for Merck to launch its new pneumococcal shot Capvaxive. | With ...

Panelists discuss how new dual-targeting agents and TKIs are redefining treatment approaches in EGFR-positive NSCLC.

US biotech Biogen (Nasdaq: BIIB) reported third-quarter 2025 revenue of $2.5 billion, up 3%, with GAAP diluted EPS of $3.17, ...

Investing.com -- Viking Therapeutics Inc (NASDAQ:VKTX) stock jumped 7.3% following the announcement that its VK2735 obesity program will be featured in multiple presentations at upcoming medical ...

Crinetics Pharmaceuticals' stock has surged after FDA approval of Palsonify for acromegaly. Click here to read the latest ...

Ascletis Pharma Inc. announces that it has selected ASC36, a once-monthly, potentially best-in-class subcutaneously ...